IPSC-CL ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 210 | Single Ventricle | 1 |
210. Single Ventricle
Clinical trials : 51 / Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05647213 (ClinicalTrials.gov) | February 3, 2023 | 30/11/2022 | Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease | Safety and Feasibility of Autologous Induced Pluripotent Stem Cells of Cardiac Lineage in Subjects With Congenital Heart Disease | Univentricular Heart;Congenital Heart Disease;Heart Failure NYHA Class III;Heart Failure NYHA Class IV | Biological: iPSC-CL | HeartWorks, Inc. | NULL | Recruiting | 18 Years | 40 Years | All | 50 | Phase 1 | United States |